The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

Recruiting Phase 3 Interventional Study
Venous Thromboembolism Postpartum Period Aspirin Low Molecular Weight Heparin
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 3
Study type
Interventional
Purpose
Prevention
Participants needed
8,805 (estimated)
Sponsor
University of Calgary · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * ONE (or more) First Order Criterion: 1. Known inherited thrombophilia diagnosed prior to enrolment, regardless of family history of VTE: i. Heterozygous factor V Leiden, or ii. Heterozygous prothrombin gene variant, or iii. Protein C deficiency, or iv. Protein S defic…
Contacts

Leslie Skeith, MD

403-944-5246

laskeith@ucalgary.ca

CONTACT

Jill Baxter, BSc

403-220-7103

jbaxter@ucalgary.ca

CONTACT